探戈治疗公司2024年第四季度GAAP每股收益$(0.35)低于预期$(0.34),销售额为$4.12百万低于预期$7.77百万

财报速递2025-02-27
探戈治疗有限公司(Tango Therapeutics,NASDAQ:TNGX)报告称,季度每股亏损$(0.35),低于分析师普遍预期的$(0.34),差距为2.94%。与去年同期每股亏损$(0.32)相比,这一数字下降了9.37%。该公司报告季度销售额为$4.12百万,低于分析师普遍预期的$7.77百万,差距为46.99%。相比去年同期销售额$5.43百万,下降了24.19%。

以上内容来自Benzinga Earnings专栏,原文如下:

Tango Therapeutics (NASDAQ:TNGX) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate of $(0.34) by 2.94 percent. This is a 9.37 percent decrease over losses of $(0.32) per share from the same period last year. The company reported quarterly sales of $4.12 million which missed the analyst consensus estimate of $7.77 million by 46.99 percent. This is a 24.19 percent decrease over sales of $5.43 million the same period last year.

免责声明:本文观点仅代表作者个人观点,不构成本平台的投资建议,本平台不对文章信息准确性、完整性和及时性做出任何保证,亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白
发表看法